Navigation Links
US HIFU Announces That 18 Recurrent Prostate Cancer Clinical Trial Sites Are Open For Enrollment

CHARLOTTE, N.C., Nov. 9, 2010 /PRNewswire/ -- USHIFU LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 (Sonablate) and Sonatherm® 600 medical devices, is pleased to announce that 18 clinical trial sites involved in the recurrent prostate cancer trial have been initiated and opened. The recurrent prostate cancer trial, or STAR trial, is a multi-center clinical study of HIFU with the Sonablate device (Sonablate HIFU) for the treatment of locally recurrent prostate cancer following failed radiation therapy.

(Logo:  )

(Logo:  )

"It is gratifying to have nearly completed the opening of all 20 trial sites, particularly with some of the most prestigious institutions in North America," said US HIFU's CEO Steve Puckett, Jr. "I believe I represent the sentiment of all of our sites that we are moving as quickly as possible toward trial completion in eager anticipation of bringing HIFU to prostate cancer patients in this country. This has been our top priority since founding the company in 2004."

The following list represents the majority of the current clinical trial sites. In addition, two well-known and–respected facilities are located in Southeast Texas and Southern Wisconsin; visit (search term fsi003) for the most recent and comprehensive listing:SITE


Toronto, Ontario, CanadaChesapeake Urology Research Associates

Towson, Md.David Geffen School of Medicine UCLA

Los Angeles, Calif.Fox Chase Cancer Center

Philadelphia, Pa. Indiana University Medical Center

Indianapolis, Ind.Iowa Clinic

Des Moines, IowaLondon Health Sciences Centre, UWO

London, Ontario, CanadaManitoba Prostate Centre

Winnipeg, Manitoba, CanadaMetropolitan Urology

Jeffersonville, Ind.New York University School of Medicine

New York, N.Y.Specialists in Urology

Naples, Fla.Tulane University School of Medicine

New Orleans, La.University Hospitals Case Medical Center

Cleveland, OhioUniversity of Illinois

Chicago, Ill.Urologic Consultants of Southeastern Pennsylvania

Bala Cynwyd, Pa. VA Connecticut Healthcare System/Yale University

West Haven, Conn.Walter Reed Army Medical Center

Washington, D.C. A partial list of criteria for inclusion in the recurrent trial, which is now in the pivotal phase, includes:

  • Men with biopsy-confirmed, organ-confined recurrent prostate cancer
  • Ages 40-85
  • Treated with external beam radiation therapy (EBRT) two or more years prior

  • For more information on the STAR trial, including a full list of inclusion criteria, please call (877) 874-4389 or visit (click on clinical information) or (search term fsi003).  

    About USHIFU LLCUSHIFU LLC (US HIFU), a privately held healthcare company, is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. US HIFU manufactures the Sonablate® 500 medical device and is focused currently on treating primary and recurrent prostate cancer using Sonablate® HIFU. The company is engaged in ongoing research for technological advancements for the Sonablate® system or other ultrasound applications. US HIFU was founded in 2004 and is headquartered in Charlotte, N.C. Additional information can be found at

    About the Sonablate® 500The Sonablate® 500 is a minimally invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by Focus Surgery, Inc. Takai Hospital Supply Ltd. distributes the Sonablate® 500 in Southeast Asia. The Sonablate® 500 is not approved for use in the U.S. The Sonablate® 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate® 500 for the treatment of prostate cancer. HIFU for prostate cancer with the Sonablate® 500 is approved or authorized and commercially available in more than 30 countries outside the U.S.  


    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
    2. Arcadia Resources Announces Improved Fiscal 2011 Second Quarter Results
    3. Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib Development Program at 52nd American Society of Hematology Annual Meeting
    4. NxStage Announces Fourth Quarter 2010 Investor Conference Schedule
    5. Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management
    6. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
    7. Hologic Announces Fourth Quarter and Fiscal 2010 Operating Results
    8. Accuray Announces Results for First Quarter of Fiscal 2011
    9. Mindray Announces Third Quarter 2010 Financial Results
    10. Mindray Medical Announces Participation in Upcoming Investor Conferences
    11. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
    Post Your Comments:
    (Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the ... capability and technology platform company serving the pharmaceutical, biotechnology, ... China and the United States ... meeting of shareholders held today, the Company,s shareholders voted ... the previously announced agreement and plan of merger (the ...
    (Date:11/24/2015)... , Nov. 24, 2015  In the pharmaceutical ... in an effort to quickly uncover new insights, tactics ... --> --> However, organizations ... market research project and ensure that all rules and ... industry standards. Another major barrier to efficiently launching market ...
    (Date:11/24/2015)... Nov. 24, 2015  DILON Diagnostics and GE Healthcare ... agreement for DILON to distribute GE,s Discovery NM750b Molecular ... signing of this distribution agreement will provide Dilon,s experienced ... Imaging system and is considered an initial step in ... solutions for clinicians and their patients. ...
    Breaking Medicine Technology:
    (Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
    (Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
    (Date:11/24/2015)... ... , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, ... FDA has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls ... meet the device regulations. , Come up short in an inspection and the FDA ...
    (Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... In response ... growing epidemic as deaths from prescription opioids in the United States grew 400 percent ... In 2013 alone, opioids were involved in 37 percent of all fatal drug overdoses. ...
    (Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
    Breaking Medicine News(10 mins):